Business Context and Reporting Period
Company: MyMD Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: May 21, 2024 (Event Date: May 20–23, 2024)
Context: The filing reports the completion of private placements involving the issuance of new series of convertible preferred stock and warrants to accredited investors.
Key Financial Metrics
Cash Flow and Liquidity:
- Total Gross Proceeds: $14 million (raised on May 23, 2024).
- Net Proceeds: Not specified; filing notes proceeds are before deducting fees, commissions, and expenses.
- Series G Preferred Stock: 8,950 shares issued at a stated value of $1,000 per share.
- Series F-1 Preferred Stock: 5,050 shares issued at a stated value of $1,000 per share.
- Conversion Terms: Both series are convertible into common stock at a price of $1.816 per share.
- Warrants Issued:
- Series G: Short-term and standard warrants to acquire up to 4,928,416 shares each (exercise price $1.816).
- Series F-1: Short-term and standard warrants to acquire up to 1,183,921 shares each (exercise price $1.816).
- Revenue, Profit, Margins, Debt: The filing text does not provide a clear value for these operational metrics.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a periodic financial comparison. The material change is the expansion of the company's capital base through the issuance of new equity instruments (Series G and Series F-1 Preferred Stock) and the associated warrants, which were not present in the prior capital structure.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful closing of the private placements previously announced on May 21, 2024. The Certificates of Designations for both stock series were filed with the Delaware Secretary of State and became effective immediately upon filing.
Risks and Contingencies:
- Dilution: The issuance includes significant potential dilution through the conversion of preferred stock and the exercise of warrants (totaling over 12 million potential common shares).
- Terms: Specific rights and preferences of the new preferred stock are detailed in the Certificates of Designations (Exhibits 3.1 and 3.2) and are not fully summarized in the text.
Investor Verification Checklist
- Verify the exact net proceeds after deducting transaction fees and expenses.
- Review Exhibits 3.1 and 3.2 for specific liquidation preferences, dividend rights, and voting rights of the Series G and Series F-1 Preferred Stock.
- Confirm the vesting schedules and expiration dates for the short-term and standard warrants issued.
- Assess the immediate impact of the new share count on existing common stockholder ownership percentages.